caa a22 4500 475817990 CHVBK 20180406123814.0 cr unu---uuuuu 170329e20000301xx s 000 0 eng 10.1007/s002280050702 doi (NATIONALLICENCE)springer-10.1007/s002280050702 Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease [Elektronische Daten] [I. Alafuzoff, S. Helisalmi, E. H. Heinonen, K. Reinikainen, M. Hallikainen, H. Soininen, K. Koivisto] Background: A beneficial effect of selegiline (l-deprenyl) in Alzheimer's disease (AD) has been reported in several clinical studies. Methods: The brain tissue from 17 deceased patients, members of a double-blind clinical trial to assess the potential benefit of selegiline in AD, were analysed. Findings: In our study, the decrease in the Mini-Mental State Examination (MMSE) scores during the progress of the disease had been significantly influenced by selegiline treatment. Prior to death, the MMSE scores were significantly higher in those patients receiving selegiline than in those receiving placebo. However, according to our results, none of the lesions critical for AD diagnosis, such as counts of senile/neuritic plaques, neurofibrillary tangles or β-A4 load, were influenced by the selegiline treatment. Interpretation: In conclusion, according to our study, mechanisms other than neuronal degeneration seen as lesions critical for AD diagnosis are influenced by selegiline treatment, leading to the functional benefit found in AD. Springer-Verlag Berlin Heidelberg, 2000 Key words Alzheimer's disease nationallicence Selegiline nationallicence Neuropathology nationallicence Alafuzoff I. Department of Neuroscience and Neurology, Kuopio University, P-O-B 1627, Fin 70211 Kuopio, Finland e-mail: irina.alafuzoff@uku.fi Tel.: +358-17-162877; Fax: +358-17-162048, FI aut Helisalmi S. Division of Diagnostic Services, Chromosome and DNA laboratory, Kuopio University Hospital, Finland, FI aut Heinonen E. H. Orion Corporation, Orion Pharma, Finland, FI aut Reinikainen K. Orion Corporation, Orion Pharma, Finland, FI aut Hallikainen M. Department of Neurology, Kuopio University Hospital, Finland, FI aut Soininen H. Department of Neuroscience and Neurology, Kuopio University, P-O-B 1627, Fin 70211 Kuopio, Finland e-mail: irina.alafuzoff@uku.fi Tel.: +358-17-162877; Fax: +358-17-162048, FI aut Koivisto K. Seinäjoki Hospital, Finland, FI aut https://doi.org/10.1007/s002280050702 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s002280050702 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Alafuzoff I. Department of Neuroscience and Neurology, Kuopio University, P-O-B 1627, Fin 70211 Kuopio, Finland e-mail: irina.alafuzoff@uku.fi Tel.: +358-17-162877; Fax: +358-17-162048, FI aut NATIONALLICENCE 700 1- Helisalmi S. Division of Diagnostic Services, Chromosome and DNA laboratory, Kuopio University Hospital, Finland, FI aut NATIONALLICENCE 700 1- Heinonen E. H. Orion Corporation, Orion Pharma, Finland, FI aut NATIONALLICENCE 700 1- Reinikainen K. Orion Corporation, Orion Pharma, Finland, FI aut NATIONALLICENCE 700 1- Hallikainen M. Department of Neurology, Kuopio University Hospital, Finland, FI aut NATIONALLICENCE 700 1- Soininen H. Department of Neuroscience and Neurology, Kuopio University, P-O-B 1627, Fin 70211 Kuopio, Finland e-mail: irina.alafuzoff@uku.fi Tel.: +358-17-162877; Fax: +358-17-162048, FI aut NATIONALLICENCE 700 1- Koivisto K. Seinäjoki Hospital, Finland, FI aut Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer